JETA Molecular has recently developed six new assays for the increasingly popular panel of HLA TRACE™ Assays, designed to monitor the loss of HLA heterozygosity following haploidentical HSCT. All the new HLA assays target alleles from MHC Class B.
Read MoreThe HLA TRACE™ panel of assays, designed for the HLA loss of heterozygosity monitoring, is growing again with four new assays being available to our customers now. This brings the total number of HLA TRACE™ Assays to 32.
Read MoreThe new HoloGRAFT cfDNA dPCR monitoring kit, designed for the quantification of tiny amounts of cell-free DNA, serving as a biomarker of organ health in patients after solid organ transplantation, has been presented during the first-ever Innovation Forum virtual event. This webinar, organized by QIAGEN, focuses on the latest innovations in life sciences and offers exciting talks by expert scientists, among others on personalized cancer care, antibiotic resistance, mRNA vaccines or novel drug targets.
Read MoreWe are pleased to invite our customers, business partners and friends to visit our booth nr. 317 at ASHI 48th Annual Meeting held in Las Vegas, USA on October 24 - 28, 2022. Together with Omixon, JETA Molecular will be presenting innovative solutions for cell-free DNA detection, dPCR chimerism and HLA loss of heterozygosity monitoring.
Read MoreBUDAPEST, HUNGARY, June 4, 2022 /EINPresswire.com/
Omixon Biocomputing, Kft announced today that it has completed a collaborative agreement with Organ Monitoring Group to develop post-transplant monitoring product HoloGRAFT. As part of the agreement Omixon secured an exclusive option to acquire all remaining shares of Organ Monitoring Group BV (OMG) after having acquired 50% of OMG. Organ Monitoring Group BV owns some exclusive license rights to commercialize patented methods using copy-number-variant markers using digital polymerase chain reaction (dPCR) technology for transplant monitoring. The method was developed and validated by John Whitlam, MD, PhD, Clinical Lead, Kidney Transplantation at Austin Health, and colleagues at the Murdoch Children’s Research Institute in Melbourne, Australia. Omixon will fund collaborative development programs related to transplant monitoring applications while Mr Doug Bost, Founder and CEO of OMG, joins Omixon as Member, Board of Directors, and Vice-President of Transplant Monitoring Products. Financial details of the transaction were not disclosed.
Read More+31 654 136 697 ⎜ info@jetabv.com
Krommewetering 101C, Utrecht, 3543AN, The Netherlands
Copyright © JETA Molecular BV.
All Rights Reserved │Privacy Policy
